Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-09-17 21:35:57 ET · period of report 2026-09-15 · accession 0001698262-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $21.40 | +191.5K | 211.0K | +980% | +$4.10M |
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | ROTE WILLIAM E. | Chief Research Off | S - Sale+OE | $62.83 | -209.0K | 98.2K | -68% | -$13.14M |
| DMT | 2026-09-17 21:35 | 2026-09-15+ | TVTX | ROTE WILLIAM E. | Chief Research Off | M - OptEx | $0.00 | -191.5K | 0 | -100% | $0 |
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 39,000 | $25.25 | 154,745 | D | — | — | (F1) Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026. |
| 2 | Common | Common Stock | 2026-09-15 | M | A | 39,650 | $17.96 | 194,395 | D | — | — | |
| 3 | Common | Common Stock | 2026-09-15 | S | D | 63,907 | $61.99 | 130,488 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F3) The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 29,021 | $62.66 | 101,467 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F4) The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 5 | Common | Common Stock | 2026-09-15 | S | D | 3,000 | $63.65 | 98,467 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F5) The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided |
| 6 | Common | Common Stock | 2026-09-15 | S | D | 270 | $65.31 | 98,197 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. |
| 7 | Common | Common Stock | 2026-09-16 | M | A | 350 | $17.96 | 98,547 | D | — | — | |
| 8 | Common | Common Stock | 2026-09-16 | M | A | 55,000 | $15.46 | 153,547 | D | — | — | |
| 9 | Common | Common Stock | 2026-09-16 | M | A | 57,500 | $26.88 | 211,047 | D | — | — | |
| 10 | Common | Common Stock | 2026-09-16 | S | D | 65,104 | $63.12 | 145,943 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F6) The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 11 | Common | Common Stock | 2026-09-16 | S | D | 47,746 | $63.61 | 98,197 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. (F7) The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| 12 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 39,000 | $0.00 | 0 | D | $25.25 · — to 2028-05-10 | 39,000 Common Stock | (F8) The stock option is fully vested and exercisable. |
| 13 | Derivative | Employee stock option (right to buy) | 2026-09-15 | M | D | 39,650 | $0.00 | 350 | D | $17.96 · — to 2029-05-09 | 39,650 Common Stock | (F8) The stock option is fully vested and exercisable. |
| 14 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 350 | $0.00 | 0 | D | $17.96 · — to 2029-05-09 | 350 Common Stock | (F8) The stock option is fully vested and exercisable. |
| 15 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 55,000 | $0.00 | 0 | D | $15.46 · — to 2030-01-31 | 55,000 Common Stock | (F8) The stock option is fully vested and exercisable. |
| 16 | Derivative | Employee stock option (right to buy) | 2026-09-16 | M | D | 57,500 | $0.00 | 0 | D | $26.88 · — to 2031-01-21 | 57,500 Common Stock | (F8) The stock option is fully vested and exercisable. |